2386-53-0

Basic information

• Product Name: 1-DODECANESULFONIC ACID SODIUM SALT
• Synonyms: SODIUM 1-DODECANESULFONATE;SODIUM 1-DODECANESULPHONATE;SODIUM DODECANE-1-SULFONATE;SODIUM DODECANESULFONATE;SODIUM LAURYLSULFONATE;Dodecylsulfonicacid,sodiumsalt;Dodecylsulfonicacidsodiums;Sodiumdodecylsulfonate
• CAS NO: 2386-53-0
• Molecular Formula: C₁₂H₂₅O₃S*Na
• Molecular Weight: 272.38
• EINECS: 219-200-6
• Product Categories: Anionic Surfactants;Functional Materials;Sulfonate (Surfactants);Surfactants;Analytical Chemistry;HPLC Ion-Pair Reagents for Basic Samples;Ion-Pair Reagents for HPLC;Ion-pair Reagents;Pyrazoles
• Mol File: 2386-53-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: >300 °C(lit.)
• Appearance: White to light cream/Powder
• Storage Temp.: Store at +5°C to +30°C.
• Solubility: H2O: soluble25mg/mL
• Water Solubility: Soluble in water.
• BRN: 3919536
• CAS DataBase Reference: 1-DODECANESULFONIC ACID SODIUM SALT(CAS DataBase Reference)
• NIST Chemistry Reference: 1-DODECANESULFONIC ACID SODIUM SALT(2386-53-0)
• EPA Substance Registry System: 1-DODECANESULFONIC ACID SODIUM SALT(2386-53-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 22-24/25-36/37-26
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 2386-53-0(Hazardous Substances Data)

Usage

Chemical Properties

white to light cream powder

Uses

Different sources of media describe the Uses of 2386-53-0 differently. You can refer to the following data:
1. suzuki reaction
2. Sodium 1-dodecanesulfonate may be used in synthesis of metal oxide-graphene nanocomposites.

General Description

Sodium 1-dodecanesulfonate is an ion-pairing reagent and increases the retention of thiabendazole on the HPLC column during determination of thiabendazole in citrus fruit and banana. It is a surfactant standard.

Purification Methods

Recrystallise it twice from EtOH and dry it in an oven at 105o for 2hours. It picks up moisture to form the 3.5H2O. Its hydrate crystallises in several phases. [Tartar & Wright J Am Chem Soc 61 543 1939, Reed & Tartar J Am Chem Soc I 57 571 1935, Beilstein 4 III 27, 4 IV 64.]

InChI:InChI=1/C12H26O3S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1

Upstream product

• 143-15-7 1-dodecylbromide 
• 112-52-7 1-chlorododecane 
• 7757-83-7 sodium sulfite 
• 151-21-3 sodium dodecyl-sulfate 

Downstream Products

• 1172640-54-8 C₁₂H₂₅O₃S^(1-)*C₂₉H₁₈N⁽¹⁺⁾ 
• 1416251-66-5 Janus Green B dodecylsulfonate 
• 1293990-67-6 2-phenyl-9-tetradecyl-benzo[8,9]quinolizino[4,5,6,7-fed]phenanthridinylium dodecanesulfonate 
• 10147-40-7 1-Dodecanesulfonyl chloride 
• 112-52-7 1-chlorododecane 
• 75-46-7 trifluoromethan 
• 120608-94-8 Dodecane-1-sulfonic acid difluoromethyl ester 

Relevant articles and documents

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Method for virus inactivation in the presence of polyalkylene glycol as well as the pharmaceutical preparation obtained therewith

The invention relates to a pharmaceutical preparation comprising a plasma protein wherein said preparation is free of infectious agents as well as essentially free of denaturation products and is obtainable by a method that encompasses the following steps: a) addition of a polyether and a chaotropic agent to a solution comprising the plasma protein, optional lyophilization of the solution; b) inactivation of infectious agents in the presence of the polyether by a physio-chemical or chemical treatment, and c) removal of the polyether and the chaotropic agent.